[{"id":"b2fab5ad-03a3-48bf-ad69-46190141e2fe","acronym":"","url":"https://clinicaltrials.gov/study/NCT04364620","created_at":"2021-01-18T21:05:40.229Z","updated_at":"2024-07-02T16:35:16.042Z","phase":"Phase 2","brief_title":"AB-16B5 Combined With Docetaxel in Subjects With Metastatic Non-Small Cell Lung Cancer (EGIA-002)","source_id_and_acronym":"NCT04364620","lead_sponsor":"Alethia Biotherapeutics","biomarkers":" EGFR • PD-L1 • ALK","pipe":" | ","alterations":" EGFR mutation • ALK mutation","tags":["EGFR • PD-L1 • ALK"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e EGFR mutation • ALK mutation"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e docetaxel • sotevtamab (AB-16B5)"],"overall_status":"Completed","enrollment":" Enrollment 35","initiation":"Initiation: 02/23/2021","start_date":" 02/23/2021","primary_txt":" Primary completion: 12/31/2023","primary_completion_date":" 12/31/2023","study_txt":" Completion: 12/31/2023","study_completion_date":" 12/31/2023","last_update_posted":"2024-03-06"}]